Valika Ali A, Costanzo Maria Rosa
Advocate Medical Group-Midwest Heart Specialists, Oak Brook, IL, USA,
Curr Heart Fail Rep. 2014 Dec;11(4):382-92. doi: 10.1007/s11897-014-0224-6.
Acute cardiorenal syndrome, also known as cardiorenal syndrome type 1, is defined as an abrupt worsening of cardiac function that occurs in at least 30 % of patients with acute decompensated heart failure and can lead to the development of acute kidney injury. The changes in renal function that occur in this setting have variable prognostic implications, as both poorer and better outcomes have been reported when renal function worsens during treatment of heart failure decompensation. Furthermore, it remains unclear when worsening renal function is actually a manifestation of true acute kidney injury or simply an indicator of hemoconcentration. Given these gaps in the understanding of the significance of renal function changes in the setting of decompensated heart failure, it is not surprising that studies on the effects of available therapies, including diuretics, vasoactive drugs, and mechanical fluid removal have yielded inconsistent results. The purpose of this review is to analyze critically the current knowledge on the pathophysiology, epidemiology, prognosis, and treatment of acute cardiorenal syndrome.
急性心肾综合征,也称为1型心肾综合征,定义为心脏功能突然恶化,至少30%的急性失代偿性心力衰竭患者会出现这种情况,并可导致急性肾损伤的发生。在这种情况下发生的肾功能变化具有不同的预后意义,因为在心力衰竭失代偿治疗期间肾功能恶化时,既有预后较差的报道,也有预后较好的报道。此外,目前尚不清楚肾功能恶化究竟是真正急性肾损伤的表现,还是仅仅是血液浓缩的指标。鉴于在理解失代偿性心力衰竭背景下肾功能变化的意义方面存在这些差距,关于利尿剂、血管活性药物和机械液体清除等现有治疗方法效果的研究结果不一致也就不足为奇了。本综述的目的是批判性地分析目前关于急性心肾综合征的病理生理学、流行病学、预后和治疗的知识。